-
Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis
-
Chiara Cremolini, Carlotta Antoniotti, Filippo Pietrantonio, Rosa Berenato, Marco Tampellini, Chiara Baratelli, Lisa Salvatore, Federica Marmorino, Beatrice Borelli, Federico Nichetti, Paolo Bironzo, Cristina Sonetto, Maria Di Bartolomeo, Filippo de Braud, Fotios Loupakis, Alfredo Falcone, Massimo Di Maio
-
Cancer Res Treat. 2017;49(3):834-845. Published online November 15, 2016
-
DOI: https://doi.org/10.4143/crt.2016.249
-
-
 Abstract
 PDF Supplementary Material PubReader ePub
- Purpose
The purpose of this study was to evaluate progression-free survival (PFS) and objective response rate (ORR) as surrogate endpoints of overall survival (OS) in modern clinical trials investigating the efficacy of targeted agents in the second-line treatment of metastatic colorectal cancer (mCRC).
Materials and Methods
A systematic search of literature pertaining to randomized phase II and III trials evaluating targeted agents as second-line treatments for mCRC was performed. The strength of the correlation between both PFS and ORR and OS was assessed based on the Pearson’s correlation coefficient (R) and the coefficient of determination (R2).
Results
Twenty trials, including a total of 7,571 patients, met the search criteria. The median duration of post-progression survival (PPS) was 7.6 months. The median differences between experimental and control arms were 0.65 months (range, –2.4 to 3.4) for the median PFS and 0.7 months (range, –5.8 to 3.9) for the median OS. PFS and ORR showed moderate (R=0.734, R2=0.539, p < 0.001) and poor correlation (R=0.169, R2=0.029, p=0.476) with OS, respectively. No differences between anti-angiogenic agents and other drugs were evident.
Conclusion
Targeted agents investigated in the second-line treatment of mCRC provided minimal PFS gains translating into modest OS improvements. Considering both the moderate correlation between PFS and OS and the short duration of PPS, the OS should remain the preferred primary endpoint for randomized clinical trials in the second-line treatment of mCRC.
-
Citations
Citations to this article as recorded by  - Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study
Manish A. Shah, Takayuki Yoshino, Niall C. Tebbutt, Axel Grothey, Josep Tabernero, Rui-Hua Xu, Andres Cervantes, Sang Cheul Oh, Kensei Yamaguchi, Marwan Fakih, Alfredo Falcone, Christina Wu, Vi K. Chiu, Jiri Tomasek, Johanna Bendell, Marilyn Fontaine, Mat
Clinical Colorectal Cancer.2023; 22(1): 100. CrossRef - The Validity of Surrogate Endpoints in Sub Groups of Metastatic Colorectal Cancer Patients Defined by Treatment Class and KRAS Status
Heather Poad, Sam Khan, Lorna Wheaton, Anne Thomas, Michael Sweeting, Sylwia Bujkiewicz
Cancers.2022; 14(21): 5391. CrossRef - Surrogate Endpoints in Oncology: Overview of Systematic Reviews and Their Use for Health Decision Making in Mexico
Yesenia Ortiz, Christian J. Fareli, Veronica Gallegos, Esteban Hernández
Value in Health Regional Issues.2021; 26: 75. CrossRef - Primary and metastatic peritoneal surface malignancies
Delia Cortés-Guiral, Martin Hübner, Mohammad Alyami, Aditi Bhatt, Wim Ceelen, Olivier Glehen, Florian Lordick, Robert Ramsay, Olivia Sgarbura, Kurt Van Der Speeten, Kiran K. Turaga, Manish Chand
Nature Reviews Disease Primers.2021;[Epub] CrossRef - Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework
Peter Murphy, David Glynn, Sofia Dias, Robert Hodgson, Lindsay Claxton, Lucy Beresford, Katy Cooper, Paul Tappenden, Kate Ennis, Alessandro Grosso, Kath Wright, Anna Cantrell, Matt Stevenson, Stephen Palmer
Health Technology Assessment.2021; 25(76): 1. CrossRef - Combining Correlated Outcomes and Surrogate Endpoints in a Network Meta-Analysis of Colorectal Cancer Treatments
Tung Hoang, Jeongseon Kim
Cancers.2020; 12(9): 2663. CrossRef - A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer
Katy Cooper, Paul Tappenden, Anna Cantrell, Kate Ennis
British Journal of Cancer.2020; 123(11): 1686. CrossRef - PREMIUM: A French prospective multicenter observational study of factors impacting on efficacy and compliance to cetuximab treatment in first-line KRAS wild-type metastatic colorectal cancer
L. Mineur, E. François, C. Plassot, J. M. Phelip, L. Miglianico, L. M. Dourthe, N. Bonichon, L. Moreau, R. Guimbaud, D. Smith, E. Achille, R. Hervé, J. M. Bons, S. Remy, R. Faroux, A. L. Villing, A. Mahamat, I. Rabbia, P. Soulié, I. Baumgaertner, N. Mathé
PLOS ONE.2020; 15(12): e0243997. CrossRef - A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology
Alyson Haslam, Spencer P. Hey, Jennifer Gill, Vinay Prasad
European Journal of Cancer.2019; 106: 196. CrossRef - Mesure de la réponse radiologique scannographique des cancers colorectaux métastatiques : état des lieux et perspectives
Achille Fabre, Nicolas Badet, Paul Calame, Eric Delabrousse, Mylène Wespiser, Celia Turco, Christophe Borg, Marine Jary
Bulletin du Cancer.2019; 106(11): 1029. CrossRef - Risk and surrogate benefit for pediatric Phase I trials in oncology: A systematic review with meta-analysis
Marcin Waligora, Malgorzata M. Bala, Magdalena Koperny, Mateusz T. Wasylewski, Karolina Strzebonska, Rafał R. Jaeschke, Agnieszka Wozniak, Jan Piasecki, Agnieszka Sliwka, Jerzy W. Mitus, Maciej Polak, Dominika Nowis, Dean Fergusson, Jonathan Kimmelman, Ma
PLOS Medicine.2018; 15(2): e1002505. CrossRef
-
13,651
View
-
326
Download
-
12
Web of Science
-
11
Crossref
|
KCA
